Vir Biotechnology Inc.'s stock surged 56.12% during extended trading hours, driven by a trifecta of positive developments announced by the company.

The biopharmaceutical firm entered into a global strategic collaboration with Japan's Astellas Pharma to co-develop and co-commercialize VIR-5500, its experimental prostate cancer treatment. Under the deal, Vir will receive $335 million in upfront and near-term payments, including a $75 million equity investment at a 50% premium, and is eligible for up to an additional $1.37 billion in milestone payments plus royalties on ex-U.S. sales.

Simultaneously, the company reported positive updated Phase 1 clinical trial results for VIR-5500, showing a favorable safety profile with no dose-limiting toxicities and demonstrating dose-dependent anti-tumor activity. Furthermore, Vir's fourth-quarter financial results significantly exceeded analyst expectations, with revenue of $64.1 million beating estimates of $23.2 million.